Endothelial permeability in vitro and in vivo: Protective actions of ANP and omapatrilat in experimental atherosclerosis

Tomoko Ichiki, Ririko Izumi, Alessandro Cataliotti, Amy M. Larsen, Sharon M. Sandberg, John C Jr. Burnett

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Increased arterial endothelial cell permeability (ECP) is considered an initial step in atherosclerosis. Atrial natriuretic peptide (ANP) which is rapidly degraded by neprilysin (NEP) may reduce injury-induced endothelial cell leakiness. Omapatrilat represents a first in class of pharmacological agents which inhibits both NEP and angiotensin converting enzyme (ACE). We hypothesized that ANP prevents thrombininduced increases of ECP in human aortic ECs (HAECs) and that omapatrilat would reduce aortic leakiness and atherogenesis and enhance ANP mediated vasorelaxation of isolated aortas. Thrombin induced ECP determined by I125 albumin flux was assessed in HAECs with and without ANP pretreatment. Next we examined the effects of chronic oral administration of omapatrilat (12 mg/kg/day, n = 13) or placebo (n = 13) for 8 weeks on aortic leakiness, atherogenesis and ANP-mediated vasorelaxation in isolated aortas in a rabbit model of atherosclerosis produced by high cholesterol diet. In HAECs, thrombin-induced increases in ECP were prevented by ANP. Omapatrilat reduced the area of increased aortic leakiness determined by Evans-blue dye and area of atheroma formation assessed by Oil-Red staining compared to placebo. In isolated arterial rings, omapatrilat enhanced vasorelaxation to ANP compared to placebo with and without the endothelium. ANP prevents thrombin-induced increases in ECP in HAECs. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP. These studies support the therapeutic potential of dual inhibition of NEP and ACE in the prevention of increased arterial ECP and atherogenesis which may be linked to the ANP/cGMP system.

Original languageEnglish (US)
Pages (from-to)21-26
Number of pages6
JournalPeptides
Volume48
DOIs
StatePublished - 2013

Fingerprint

Atrial Natriuretic Factor
Permeability
Atherosclerosis
Endothelial cells
Endothelial Cells
Vasodilation
Neprilysin
Thrombin
Placebos
Peptidyl-Dipeptidase A
Atherosclerotic Plaques
Oral Administration
Aorta
omapatrilat
In Vitro Techniques
Evans Blue
Nutrition
Endothelium
Albumins
Oils

Keywords

  • Angiotensin converting enzyme inhibitor
  • Atherosclerosis
  • Atrial natriuretic peptides
  • Endothelium
  • Neprilysin inhibitor

ASJC Scopus subject areas

  • Biochemistry
  • Endocrinology
  • Physiology
  • Cellular and Molecular Neuroscience

Cite this

Endothelial permeability in vitro and in vivo : Protective actions of ANP and omapatrilat in experimental atherosclerosis. / Ichiki, Tomoko; Izumi, Ririko; Cataliotti, Alessandro; Larsen, Amy M.; Sandberg, Sharon M.; Burnett, John C Jr.

In: Peptides, Vol. 48, 2013, p. 21-26.

Research output: Contribution to journalArticle

Ichiki, Tomoko ; Izumi, Ririko ; Cataliotti, Alessandro ; Larsen, Amy M. ; Sandberg, Sharon M. ; Burnett, John C Jr. / Endothelial permeability in vitro and in vivo : Protective actions of ANP and omapatrilat in experimental atherosclerosis. In: Peptides. 2013 ; Vol. 48. pp. 21-26.
@article{a27eeeebc5eb493eb51a4dad6ff8bb5e,
title = "Endothelial permeability in vitro and in vivo: Protective actions of ANP and omapatrilat in experimental atherosclerosis",
abstract = "Increased arterial endothelial cell permeability (ECP) is considered an initial step in atherosclerosis. Atrial natriuretic peptide (ANP) which is rapidly degraded by neprilysin (NEP) may reduce injury-induced endothelial cell leakiness. Omapatrilat represents a first in class of pharmacological agents which inhibits both NEP and angiotensin converting enzyme (ACE). We hypothesized that ANP prevents thrombininduced increases of ECP in human aortic ECs (HAECs) and that omapatrilat would reduce aortic leakiness and atherogenesis and enhance ANP mediated vasorelaxation of isolated aortas. Thrombin induced ECP determined by I125 albumin flux was assessed in HAECs with and without ANP pretreatment. Next we examined the effects of chronic oral administration of omapatrilat (12 mg/kg/day, n = 13) or placebo (n = 13) for 8 weeks on aortic leakiness, atherogenesis and ANP-mediated vasorelaxation in isolated aortas in a rabbit model of atherosclerosis produced by high cholesterol diet. In HAECs, thrombin-induced increases in ECP were prevented by ANP. Omapatrilat reduced the area of increased aortic leakiness determined by Evans-blue dye and area of atheroma formation assessed by Oil-Red staining compared to placebo. In isolated arterial rings, omapatrilat enhanced vasorelaxation to ANP compared to placebo with and without the endothelium. ANP prevents thrombin-induced increases in ECP in HAECs. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP. These studies support the therapeutic potential of dual inhibition of NEP and ACE in the prevention of increased arterial ECP and atherogenesis which may be linked to the ANP/cGMP system.",
keywords = "Angiotensin converting enzyme inhibitor, Atherosclerosis, Atrial natriuretic peptides, Endothelium, Neprilysin inhibitor",
author = "Tomoko Ichiki and Ririko Izumi and Alessandro Cataliotti and Larsen, {Amy M.} and Sandberg, {Sharon M.} and Burnett, {John C Jr.}",
year = "2013",
doi = "10.1016/j.peptides.2013.07.020",
language = "English (US)",
volume = "48",
pages = "21--26",
journal = "Peptides",
issn = "0196-9781",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Endothelial permeability in vitro and in vivo

T2 - Protective actions of ANP and omapatrilat in experimental atherosclerosis

AU - Ichiki, Tomoko

AU - Izumi, Ririko

AU - Cataliotti, Alessandro

AU - Larsen, Amy M.

AU - Sandberg, Sharon M.

AU - Burnett, John C Jr.

PY - 2013

Y1 - 2013

N2 - Increased arterial endothelial cell permeability (ECP) is considered an initial step in atherosclerosis. Atrial natriuretic peptide (ANP) which is rapidly degraded by neprilysin (NEP) may reduce injury-induced endothelial cell leakiness. Omapatrilat represents a first in class of pharmacological agents which inhibits both NEP and angiotensin converting enzyme (ACE). We hypothesized that ANP prevents thrombininduced increases of ECP in human aortic ECs (HAECs) and that omapatrilat would reduce aortic leakiness and atherogenesis and enhance ANP mediated vasorelaxation of isolated aortas. Thrombin induced ECP determined by I125 albumin flux was assessed in HAECs with and without ANP pretreatment. Next we examined the effects of chronic oral administration of omapatrilat (12 mg/kg/day, n = 13) or placebo (n = 13) for 8 weeks on aortic leakiness, atherogenesis and ANP-mediated vasorelaxation in isolated aortas in a rabbit model of atherosclerosis produced by high cholesterol diet. In HAECs, thrombin-induced increases in ECP were prevented by ANP. Omapatrilat reduced the area of increased aortic leakiness determined by Evans-blue dye and area of atheroma formation assessed by Oil-Red staining compared to placebo. In isolated arterial rings, omapatrilat enhanced vasorelaxation to ANP compared to placebo with and without the endothelium. ANP prevents thrombin-induced increases in ECP in HAECs. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP. These studies support the therapeutic potential of dual inhibition of NEP and ACE in the prevention of increased arterial ECP and atherogenesis which may be linked to the ANP/cGMP system.

AB - Increased arterial endothelial cell permeability (ECP) is considered an initial step in atherosclerosis. Atrial natriuretic peptide (ANP) which is rapidly degraded by neprilysin (NEP) may reduce injury-induced endothelial cell leakiness. Omapatrilat represents a first in class of pharmacological agents which inhibits both NEP and angiotensin converting enzyme (ACE). We hypothesized that ANP prevents thrombininduced increases of ECP in human aortic ECs (HAECs) and that omapatrilat would reduce aortic leakiness and atherogenesis and enhance ANP mediated vasorelaxation of isolated aortas. Thrombin induced ECP determined by I125 albumin flux was assessed in HAECs with and without ANP pretreatment. Next we examined the effects of chronic oral administration of omapatrilat (12 mg/kg/day, n = 13) or placebo (n = 13) for 8 weeks on aortic leakiness, atherogenesis and ANP-mediated vasorelaxation in isolated aortas in a rabbit model of atherosclerosis produced by high cholesterol diet. In HAECs, thrombin-induced increases in ECP were prevented by ANP. Omapatrilat reduced the area of increased aortic leakiness determined by Evans-blue dye and area of atheroma formation assessed by Oil-Red staining compared to placebo. In isolated arterial rings, omapatrilat enhanced vasorelaxation to ANP compared to placebo with and without the endothelium. ANP prevents thrombin-induced increases in ECP in HAECs. Chronic oral administration of omapatrilat reduces aortic leakiness and atheroma formation with enhanced endothelial independent vasorelaxation to ANP. These studies support the therapeutic potential of dual inhibition of NEP and ACE in the prevention of increased arterial ECP and atherogenesis which may be linked to the ANP/cGMP system.

KW - Angiotensin converting enzyme inhibitor

KW - Atherosclerosis

KW - Atrial natriuretic peptides

KW - Endothelium

KW - Neprilysin inhibitor

UR - http://www.scopus.com/inward/record.url?scp=84886931379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84886931379&partnerID=8YFLogxK

U2 - 10.1016/j.peptides.2013.07.020

DO - 10.1016/j.peptides.2013.07.020

M3 - Article

C2 - 23927843

AN - SCOPUS:84886931379

VL - 48

SP - 21

EP - 26

JO - Peptides

JF - Peptides

SN - 0196-9781

ER -